CRISPR Therapeutics AG
CRSP | NASDAQ
$51.40
-$2.86 (-5.27%)
At close: Oct 30, 2026, 3:59 PM ET
$52.27
+$0.87 (+1.69%)
Pre-market:
Nov 2, 2026, 7:11 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 3.51M | 35M | 370M | 436K | 913.08M | 719K |
Cost of Revenue | 232.96M | 110.25M | 130.25M | 110.25M | 101.18M | 269.41M |
Gross Profit | -229.45M | -75.25M | 239.75M | -109.81M | 811.9M | -268.69M |
Operating Income | -568.32M | -466.57M | -222.54M | -673.16M | 373.53M | -354.44M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -577.97M | -362.67M | -150.72M | -650.5M | 379.53M | -348.06M |
Net Income | -581.6M | -366.25M | -153.61M | -650.18M | 377.66M | -348.87M |
Selling & General & Admin | 73.54M | 72.98M | 76.16M | 102.46M | 99.69M | 85.75M |
Research & Development | 265.33M | 320.65M | 387.33M | 461.65M | 340.57M | 221.38M |
Other Expenses | n/a | -2.31M | -1.21M | -762K | -1.88M | -221.38M |
Operating Expenses | 338.87M | 391.32M | 462.29M | 563.35M | 438.38M | 85.75M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 571.83M | 501.57M | 592.54M | 673.6M | 539.55M | 355.15M |
Income Tax Expense | 3.63M | 3.59M | 2.89M | -325K | 1.87M | 809K |
Shares Outstanding (Basic) | 89.93M | 84.36M | 79.22M | 77.75M | 75.95M | 65.95M |
Shares Outstanding (Diluted) | 89.93M | 84.36M | 79.22M | 77.75M | 80.39M | 65.95M |
EPS (Basic) | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 |
EPS (Diluted) | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 |
EBITDA | -558.49M | -343.41M | -130.89M | -626.33M | 397.48M | -345.25M |
EBIT | -577.97M | -362.67M | -150.72M | -650.5M | 379.53M | -354.44M |
Depreciation & Amortization | 19.48M | 19.26M | 19.84M | 24.17M | 17.95M | 9.18M |
Add to Watchlist
Select watchlists to add or remove CRSP